Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2018

Open Access 01-12-2018 | Research article

Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines

Authors: April M. Jorge, Ronald B. Melles, Yuqing Zhang, Na Lu, Sharan K. Rai, Lucy H. Young, Karen H. Costenbader, Rosalind Ramsey-Goldman, S. Sam Lim, John M. Esdaile, Ann E. Clarke, M. B. Urowitz, Anca Askanase, Cynthia Aranow, Michelle Petri, Hyon Choi

Published in: Arthritis Research & Therapy | Issue 1/2018

Login to get access

Abstract

Background

Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing. However, contemporary HCQ prescribing trends in the UK remain unknown.

Methods

We examined a UK general population database to investigate HCQ dosing between 2007 and 2016. We studied trends of excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW) and determined their independent predictors using multivariable logistic regression analyses.

Results

Among 20,933 new HCQ users (78% female), the proportions of initial HCQ excess dosing declined from 40% to 36% using IBW and 38% to 30% using ABW, between 2007 and 2016. Among these, 47% of women were excess-dosed (multivariable OR 12.52; 95% CI 10.99–14.26) using IBW and 38% (multivariable OR 1.98; 95% CI,1.81–2.15) using ABW. Applying IBW, 37% of normal and 44% of obese patients were excess-dosed; however, applying ABW, 53% of normal and 10% of obese patients were excess-dosed (multivariable ORs = 1.61 and 0.1 (reference = normal); both p < 0.01). Long-term HCQ users showed similar excess dosing.

Conclusion

A substantial proportion of HCQ users in the UK, particularly women, may have excess HCQ dosing per the previous or recent weight-based guidelines despite a modest decline in recent years. Over half of normal-BMI individuals were excess-dosed per the latest guidelines. This implies the potential need to reduce dosing for many patients but also calls for further research to establish unifying evidence-based safe and effective dosing strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus. 2008;17(4):271–3.CrossRefPubMed Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus. 2008;17(4):271–3.CrossRefPubMed
2.
go back to reference Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195–205.CrossRefPubMed Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195–205.CrossRefPubMed
3.
go back to reference A Randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian hydroxychloroquine study group. N Engl J Med. 1991;324:150–4.CrossRef A Randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian hydroxychloroquine study group. N Engl J Med. 1991;324:150–4.CrossRef
4.
go back to reference Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vila LM, Reveille JD, Group LS. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–72.CrossRefPubMedPubMedCentral Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vila LM, Reveille JD, Group LS. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–72.CrossRefPubMedPubMedCentral
5.
go back to reference Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011;13:77–80.CrossRefPubMed Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011;13:77–80.CrossRefPubMed
6.
go back to reference Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640–7.CrossRefPubMed Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640–7.CrossRefPubMed
7.
go back to reference Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012;21:1178–82.CrossRefPubMed Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012;21:1178–82.CrossRefPubMed
8.
go back to reference O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–18.CrossRefPubMed O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–18.CrossRefPubMed
9.
go back to reference Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, Leatherman S, Mikuls TR, Anis AH. Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Ann Intern Med. 2017;167(1):8–16. Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, Leatherman S, Mikuls TR, Anis AH. Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Ann Intern Med. 2017;167(1):8–16.
10.
go back to reference Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–8.CrossRefPubMed Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–8.CrossRefPubMed
11.
go back to reference Costedoat-Chalumeau N, Dunogue B, Leroux G, Morel N, Jallouli M, Le Guern V, Piette JC, Brezin AP, Melles RB, Marmor MF. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol. 2015;49(3):317–26.CrossRefPubMed Costedoat-Chalumeau N, Dunogue B, Leroux G, Morel N, Jallouli M, Le Guern V, Piette JC, Brezin AP, Melles RB, Marmor MF. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol. 2015;49(3):317–26.CrossRefPubMed
12.
go back to reference Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40(8):1482–6. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40(8):1482–6.
13.
go back to reference Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology. 2003;110(7):1321–6.CrossRefPubMed Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology. 2003;110(7):1321–6.CrossRefPubMed
14.
go back to reference Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62(6):775–84.CrossRef Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62(6):775–84.CrossRef
15.
go back to reference Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity. Rheumatology. 2016;55(6):957–67.CrossRefPubMed Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity. Rheumatology. 2016;55(6):957–67.CrossRefPubMed
16.
go back to reference Bourke BJ, Jones S, Rajammal AK, Silman A, Smith R. Hydroxychloroquine and ocular toxicity recommendations on screening. The Royal College of Ophthalmologists in association with The British Society for Rheumatology and the British Association of Dermatologists. 2009. Bourke BJ, Jones S, Rajammal AK, Silman A, Smith R. Hydroxychloroquine and ocular toxicity recommendations on screening. The Royal College of Ophthalmologists in association with The British Society for Rheumatology and the British Association of Dermatologists. 2009.
17.
go back to reference Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.CrossRefPubMed Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.CrossRefPubMed
18.
go back to reference Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–60.CrossRefPubMed Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–60.CrossRefPubMed
19.
go back to reference Melles RB, Marmor MF. The prevalence of hydroxychloroquine retinopathy and toxic dosing, and the role of the ophthalmologist in reducing both. Am J Ophthalmol. 2016;170:240.CrossRefPubMed Melles RB, Marmor MF. The prevalence of hydroxychloroquine retinopathy and toxic dosing, and the role of the ophthalmologist in reducing both. Am J Ophthalmol. 2016;170:240.CrossRefPubMed
20.
go back to reference Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. American Academy of O: recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–94.CrossRefPubMed Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. American Academy of O: recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–94.CrossRefPubMed
21.
go back to reference Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. American Journal of Medicine. 1983;75:40–5. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. American Journal of Medicine. 1983;75:40–5.
22.
go back to reference Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110(7):1321–6.CrossRefPubMed Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110(7):1321–6.CrossRefPubMed
23.
go back to reference Marmor MF. Hydroxychloroquine screening alert: change is in the wind. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):96–8.CrossRefPubMed Marmor MF. Hydroxychloroquine screening alert: change is in the wind. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):96–8.CrossRefPubMed
24.
go back to reference Kim JE, Marmor MF. Update on screening recommendations for hydroxychloroquine retinopathy. JAMA Ophthalmol. 2016;134(7):849.CrossRefPubMed Kim JE, Marmor MF. Update on screening recommendations for hydroxychloroquine retinopathy. JAMA Ophthalmol. 2016;134(7):849.CrossRefPubMed
25.
go back to reference Tucker WR, Galloway J, Walsh S. The gathering storm: hydroxychloroquine retinopathy screening in the U.K. Br J Dermatol. 2017;176(6):1420–1.CrossRefPubMed Tucker WR, Galloway J, Walsh S. The gathering storm: hydroxychloroquine retinopathy screening in the U.K. Br J Dermatol. 2017;176(6):1420–1.CrossRefPubMed
27.
go back to reference Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of ophthalmology. Opthamology. 2002;109(7):1377–82.CrossRef Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of ophthalmology. Opthamology. 2002;109(7):1377–82.CrossRef
28.
go back to reference Blak BT, et al. Generalisability of the health improvement network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251–5.PubMed Blak BT, et al. Generalisability of the health improvement network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251–5.PubMed
29.
go back to reference Plaquenil (hydroxychloroquine) [product mongraph]. Laval, Quebec, Canada: Sanofi-aventis Canada; 2018. Plaquenil (hydroxychloroquine) [product mongraph]. Laval, Quebec, Canada: Sanofi-aventis Canada; 2018.
31.
go back to reference Rod NH, Lange T, Andersen I, Marott JL, Diderichsen F. Additive interaction in survival analysis: use of the additive hazards model. Epidemiology. 2012;23(5):733–7.CrossRefPubMed Rod NH, Lange T, Andersen I, Marott JL, Diderichsen F. Additive interaction in survival analysis: use of the additive hazards model. Epidemiology. 2012;23(5):733–7.CrossRefPubMed
32.
go back to reference Eo DR, Lee MG, Ham DI, Kang SW, Lee J, Cha HS, Koh E, Kim SJ. Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J Korean Med Sci. 2017;32(3):522–7.CrossRefPubMedPubMedCentral Eo DR, Lee MG, Ham DI, Kang SW, Lee J, Cha HS, Koh E, Kim SJ. Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J Korean Med Sci. 2017;32(3):522–7.CrossRefPubMedPubMedCentral
33.
go back to reference Kobak S, Deveci H. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. Int J Rheum Dis. 2010;13(3):e11–5.CrossRefPubMed Kobak S, Deveci H. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. Int J Rheum Dis. 2010;13(3):e11–5.CrossRefPubMed
34.
go back to reference Jorge A, Rai S, Choi HK. The risk of hydroxychloroquine toxic retinopathy and its risk factors in the treatment of rheumatic diseases: a systematic review [abstract]. Arthritis Rheum. 2017;69(Suppl 10) Jorge A, Rai S, Choi HK. The risk of hydroxychloroquine toxic retinopathy and its risk factors in the treatment of rheumatic diseases: a systematic review [abstract]. Arthritis Rheum. 2017;69(Suppl 10)
35.
go back to reference Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42(11):2092–7.CrossRefPubMedPubMedCentral Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42(11):2092–7.CrossRefPubMedPubMedCentral
37.
go back to reference Walvick MD, Walvick MP, Tongson E, Ngo CH. Hydroxychloroquine: lean body weight dosing. Ophthalmology. 2011;118(10):2100. author reply 2101CrossRefPubMed Walvick MD, Walvick MP, Tongson E, Ngo CH. Hydroxychloroquine: lean body weight dosing. Ophthalmology. 2011;118(10):2100. author reply 2101CrossRefPubMed
38.
go back to reference Browning DJ, Lee C, Rotberg D. The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. Clin Ophthalmol. 2014;8:1401–7.CrossRefPubMedPubMedCentral Browning DJ, Lee C, Rotberg D. The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. Clin Ophthalmol. 2014;8:1401–7.CrossRefPubMedPubMedCentral
Metadata
Title
Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines
Authors
April M. Jorge
Ronald B. Melles
Yuqing Zhang
Na Lu
Sharan K. Rai
Lucy H. Young
Karen H. Costenbader
Rosalind Ramsey-Goldman
S. Sam Lim
John M. Esdaile
Ann E. Clarke
M. B. Urowitz
Anca Askanase
Cynthia Aranow
Michelle Petri
Hyon Choi
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2018
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-018-1634-8

Other articles of this Issue 1/2018

Arthritis Research & Therapy 1/2018 Go to the issue